ID   HCC827 ER1
AC   CVCL_EJ07
SY   HCC827-ER1; HCC 827 ER1; ER1
DR   cancercelllines; CVCL_EJ07
DR   Cosmic; 1716792
DR   GEO; GSM935084
DR   Wikidata; Q54881783
RX   PubMed=22751098;
RX   PubMed=32928921;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 12
//
RX   PubMed=22751098; DOI=10.1038/ng.2330;
RA   Zhang Z.-F., Lee J.C., Lin L.-P., Olivas V., Au V., LaFramboise T.,
RA   Abdel-Rahman M., Wang X.-Q., Levine A.D., Rho J.K., Choi Y.J.,
RA   Choi C.-M., Kim S.-W., Jang S.J., Park Y.S., Kim W.S., Lee D.H.,
RA   Lee J.-S., Miller V.A., Arcila M.E., Ladanyi M., Moonsamy P.,
RA   Sawyers C.L., Boggon T.J., Ma P.C., Costa C., Taron M., Rosell R.,
RA   Halmos B., Bivona T.G.;
RT   "Activation of the AXL kinase causes resistance to EGFR-targeted
RT   therapy in lung cancer.";
RL   Nat. Genet. 44:852-860(2012).
//
RX   PubMed=32928921; DOI=10.1158/0008-5472.CAN-20-1634;
RA   Sun Y.-T., Meyers B.A., Czako B., Leonard P., Mseeh F., Harris A.L.,
RA   Wu Q., Johnson S., Parker C.A., Cross J.B., Di Francesco M.E.,
RA   Bivona B.J., Bristow C.A., Burke J.P., Carrillo C.C., Carroll C.L.,
RA   Chang Q., Feng N.-P., Gao G., Gera S., Giuliani V., Huang J.K.,
RA   Jiang Y.-Y., Kang Z.-J., Kovacs J.J., Liu C.-Y., Lopez A.M., Ma X.-Y.,
RA   Mandal P.K., McAfoos T., Miller M.A., Mullinax R.A., Peoples M.,
RA   Ramamoorthy V., Seth S., Spencer N.D., Suzuki E., Williams C.C.,
RA   Yu S.S., Zuniga A.M., Draetta G.F., Marszalek J.R., Heffernan T.P.,
RA   Kohl N.E., Jones P.;
RT   "Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and
RT   EGFR-independent resistance mechanisms toward osimertinib.";
RL   Cancer Res. 80:4840-4853(2020).
//